In today’s briefing:
- TeNor Therapeutics (丹诺医药) Pre-IPO Quick Comment: Strong Innovation Constrained by Commercial Outlook
TeNor Therapeutics (丹诺医药) Pre-IPO Quick Comment: Strong Innovation Constrained by Commercial Outlook
- TeNor Terapeutics, a China-based clinical-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC and ABCI are the joint book runners.
- In this note, we look at the company’s core products, rifasutenizol, rifaquizinone, and TNP-2092, and assess the selling point around the core product.
- We also look at the company’s pre-IPO investors and management team.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
